Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 9, 2012

Quanta to Incorporate ZyGEM’s RNA Extraction Solution into Quantitative PCR Kits

  • ZyGEM is partnering with Quanta BioSciences to incorporate ZyGEM's enzymatic RNA extraction technology into Quanta's quantitative PCR reagents. ZyGEM's RNAGem technology can be used with diverse samples, and Quanta’s reagents enable gene expression, pathogen detection, and genetic analyses in various industries including pharmaceutical R&D, diagnostics, agribusiness, and biodefense.

    ZyGEM explains that its enzymatic technology uses a single tube process to provide complete extraction of RNA including smaller RNA molecules such as noncoding RNA and microRNA that are excluded by other extraction methods. It delivers higher molecular weight RNA and more representative transcriptome profiles than other methods and is well suited for complete gene expression and noncoding RNA analyses. The technology has been shown to produce consistent, linear yields of nuclear RNA, thereby ensuring 100% reproducible results, according to ZyGEM. 

    “In our testing ZyGEM's technology rapidly produced high-quality RNA, and we believe our customers will welcome the opportunity to obtain these benefits in their own work,” says David Schuster, director of R&D at Quanta BioSciences, with regard to this OEM agreement.

    Paul Kinnon, CEO of ZyGEM, remarks, “ZyGEM's RNA extraction technology represents a significant advance in sample preparation for RNA-based testing and analysis, and we are pleased to partner with leading reagent producer Quanta BioSciences to expand its availability. This agreement reinforces our strategy of partnering with innovative companies to bring the advantages of our accurate, fast, and simple RNA and DNA extraction technologies to researchers around the globe.”

    Earlier this year ZyGEM made arrangements to bolster use of its extraction technologies in Sweden and the Middle East. In May it inked a nonexclusive agreement with TATAA Biocenter for distribution of its DNA and RNA extraction products in Sweden and other selected countries worldwide. In January, ZyGEM signed an OEM agreement with Saudi Diagnostics.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »